New business models for antibiotic innovation

Area of Science:

• Microbiology
• Pharmaceutical Sciences
• Public Health Policy

Background:

• Rising antibiotic resistance and a lack of new drugs pose significant global health and policy challenges.
• Existing financial, scientific, and regulatory hurdles impede the development of novel antibiotics.
• New business models are essential to overcome these barriers and incentivize antibiotic innovation.

Purpose of the Study:

• To explore innovative business models and strategies for antibiotic research and development (R&D).
• To address the financial, scientific, and regulatory challenges hindering antibiotic innovation.
• To propose solutions that promote the discovery and market entry of novel antibiotics.

Main Methods:

• Analysis of existing financial, scientific, and regulatory challenges in antibiotic R&D.
• Evaluation of pull-incentives (paying for R&D outputs) and push-incentives (paying for R&D inputs).
• Discussion of regulatory strategies, including companion diagnostics, parallel testing, and data transparency.
• Consideration of a tax on non-human antibiotic use and a collaborative R&D approach (3Rs: sharing resources, risks, and rewards).

Main Results:

• Financial incentives, such as delinking return on investment from sales revenue, can boost innovation and promote rational antibiotic use.
• Regulatory agencies can facilitate development by encouraging companion diagnostics, parallel testing, and transparent clinical trial data sharing.
• A tax on non-human antibiotic use could discourage non-therapeutic applications.
• Collaborative R&D models focusing on shared resources, risks, and rewards are crucial for novel antibiotic development.

Conclusions:

• Overcoming antibiotic resistance necessitates innovative business models that incentivize R&D.
• A combination of financial, regulatory, and collaborative strategies can effectively drive the development of novel antibiotics.
• Delinking financial returns from sales and fostering collaboration are key to ensuring a sustainable pipeline of new antimicrobial drugs.